Anti-Human CD126/IL6R & ALB Bispecific Reference Antibody (Vobarilizumab, RUO)
- Catalog number: BS10174
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Vobarilizumab (BS10174) is a research-grade recombinant antibody targeting CD126. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: VH-VH'
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: sIL6R,Interleukin-6receptorsubunitalpha,CD126,IL-6R1,IL-6Rsubunitalpha,Membraneglycoprotein80,gp80,IL6R,IL-6RA,IL-6receptorsubunitalpha,IL-6R-alpha,ALB,Albumin
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,(20A11-9mer-ALB11),ALX-0061,CAS:1628814-88-9
Background: Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: VH-VH'
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: sIL6R,Interleukin-6receptorsubunitalpha,CD126,IL-6R1,IL-6Rsubunitalpha,Membraneglycoprotein80,gp80,IL6R,IL-6RA,IL-6receptorsubunitalpha,IL-6R-alpha,ALB,Albumin
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,(20A11-9mer-ALB11),ALX-0061,CAS:1628814-88-9
Background: Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.
Note: For research use only. Not suitable for clinical or therapeutic use.
Image Data
No validation image data is currently available for this product.
